SCHEMBL10272489

SCHEMBL10272489

CCc1ncc(-c2ccc(OC)cc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CLK4 Q9HAZ1 2/20 0.46
ESR2 Q92731 1/20 0.45
DYRK1A Q13627 3/20 0.44
CYP17A1 P05093 1/20 0.44
CASP3 P42574 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
AURKB Q96GD4 2/20 0.43
PLK4 O00444 1/20 0.43
AURKA O14965 1/20 0.43
DYRK3 O43781 1/20 0.43
MAP4K4 O95819 1/20 0.43
NTRK1 P04629 1/20 0.43
INSR P06213 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28789379 0.80 PTGS2 (0.47) MCHR1NPC1RAB9APDGFRBPDGFRA
SCHEMBL10272514 0.79 LMNA (0.40) NPC1RAB9AKDM4ESMN1; SMN2CA12
SCHEMBL14037485 0.78 DYRK1A (0.53) NPC1RAB9APDGFRBPDGFRAKDM4E
SCHEMBL17411218 0.78 NPSR1 (0.43) NPC1RAB9APDGFRBPDGFRAKDM4E
SCHEMBL12735002 0.78 METAP2 (0.44) NPC1RAB9ASMN1; SMN2CYP17A1
SCHEMBL634325 0.76 CDC25A (0.59) PDGFRBPDGFRAKDM4ECLK4ESR2
SCHEMBL1735138 0.76 PDGFRB (0.49) NPC1RAB9APDGFRBPDGFRAKDM4E
SCHEMBL16542181 0.76 IDO1 (0.34) NPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL12514799 0.76 NPC1 (0.50) NPC1RAB9AKDM4ESMN1; SMN2MAPK1
SCHEMBL12092479 0.75 RAB9A (0.54) NPC1RAB9APDGFRBPDGFRASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160101104-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2016-04-14 US disclosed
US-8309577-B2 Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-13 US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 MCHR1 256/4885NPC1 896/4885RAB9A 333/4885
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 MCHR1 256/4885NPC1 896/4885RAB9A 333/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 MCHR1 256/4885NPC1 896/4885RAB9A 333/4885
US-20160101104-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 MCHR1 256/4885NPC1 896/4885RAB9A 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.